The website you are visiting is protected and accelerated by Imperva. Your computer may have been infected by malware and ...

OptiNose (NASDAQ:OPTN) stock surges 61% as Paratek Pharmaceuticals agrees to a $330M acquisition. Read mroe here.

Paratek Pharmaceuticals is betting that OptiNose’s chronic rhinosinusitis treatment will be a partner to its antibiotic ...

OptiNose Inc. OPTN) on Wednesday reported a loss of $360,000 in its fourth quarter.

OptiNose Inc (NASDAQ:OPTN) shares are trading higher Thursday after Paratek Pharmaceuticals announced a deal to acquire the company.

In a move to expand its portfolio beyond antibiotics, Paratek Pharmaceuticals has bought out Optinose and its chronic ...

Fintel reports that on March 21, 2025, Piper Sandler downgraded their outlook for OptiNose (NasdaqGS:OPTN) from Overweight to ...

Reports Q4 revenue $22.418M, consensus $20.82M.Light Up your Portfolio with Spark:Easily identify stocks' risks and opportunities. Discover ...

Fintel reports that on March 20, 2025, Lake Street downgraded their outlook for OptiNose (NasdaqGS:OPTN) from Buy to Hold.

Company reports fourth quarter and full year 2024 XHANCE net revenue of $22.4 million and $78.2 million, increases of 13% and 10% compared to ...